Teva Pharmaceutical Industries Limited (TEVA) 10-Q2022 Q1 Quarterly report

Filed: 3 May 22, 4:06pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	8th grade Avg

New words: Abbreviated, abovementioned, absolute, acquiree, adalimumab, Adapt, Advair, agent, Amneal, annum, arbitration, arranged, Arranger, Baltimore, Banca, bifurcated, bilateral, BNP, Brazil, causation, cease, cell, Certiorari, Chase, Citibank, codefendant, Concurrently, conflict, contact, Council, CRL, customary, DAC, deadline, denial, deutetrabenazine, devaluation, dexamethasone, disruption, drawdown, EBSI, embedded, ensure, entitled, escalation, ESG, fee, Fluticasone, FWK, gas, Goldman, greenhouse, hereto, HSBC, IMI, immunology, implausible, Inesa, institute, interlocutory, invasion, IP, Island, ITC, JPMorgan, judgement, Kinney, KPH, lifesaving, linked, LLC, low, lymphoma, Lynch, Madison, Mandated, mantle, maximum, Mayor, meantime, medicine, Meijer, Merrill, mitigate, Mitsui, Mizuho, Morgan, movement, MUFG, myelodysplastic, myeloma, Narcan, nasal, Nassau, neurodegeneration, neuroscience, newly, Novetide, ntangible, nuisance, outlined, overarching, ownership, Paolo, payor, permanently, plc, PNC, population, Powder, preliminarily, premium, prescription, pressure, Propionate, qualified, reassert, recasting, recommence, reduction, relationship, Rhode, Salmeterol, Salvoy, Score, SeeNo, small, Social, societal, SOFR, solvency, spray, Stanley, substantively, Suffolk, Sumitomo, supplemental, Trademark, transparency, Ukraine, unclear, undrawn, unfavorable, unpaid, vast, Writ, wrongdoing

Removed: aerosol, albuterol, argument, Australian, Celltrion, cessation, charge, Cipla, clinically, compensating, computation, Davie, decided, defendant, disallowance, EBITDA, economy, enacted, enactment, enumerated, evaluation, exercised, expired, franchise, gathered, gradually, heard, Herzuma, HFA, hryvnia, idle, IMS, incremental, inhaler, instructed, largest, leaving, lidocaine, Lidoderm, magistrate, methodology, Nuvelution, observed, overruled, partnership, patch, pediatric, positively, primary, ProAir, profitability, promote, quickly, recognize, recommended, redeemed, removing, requiring, restriction, retailer, Rimsa, simplify, slightly, stake, step, stipulated, straight, sulfate, syndrome, Tennessee, Tourette, transdermal, Ukrainian, upcoming, Ventolin, warning

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated TEVA transcripts

TEVA similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32

CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Teva Pharmaceutical Industries Limited (the “Company”) on Form 10-Q for the period ended March 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), we, Kåre Schultz, President and Chief Executive Officer of the Company, and Eli Kalif, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that:

(1)

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: May 3, 2022

/s/ Kåre Schultz

Kåre Schultz

President and Chief Executive Officer

/s/ Eli Kalif

Eli Kalif

Executive Vice President, Chief Financial Officer